Andrew B. Lassman, MD

Academic Appointments

John Harris Associate Professor of Neurology

Current Administrative Positions

Chief, Division of Neuro-Oncology
Co-Director, Brain Tumor Center
Associate Director for Clinical Trials, Herbert Irving Comprehensive Cancer Center

Andrew B. Lassman, MD, is the John Harris Associate Professor of Neurology and the Chief of Neuro-oncology at Columbia University Irving Medical Center and serves as the Associate Director for Clinical Trials at the Herbert Irving Comprehensive Cancer Center. His research and clinical efforts focus on improving the understanding and treatment of brain tumors. Specifically, his research interests focus on translational clinical trials for brain tumors with molecular correlative analyses to understand the reasons for treatment success or failure, and to refine treatment paradigms. Dr. Lassman has led retrospective studies, single institution prospective clinical trials, and multicenter prospective trials conducted nationally through the National Cancer Institute sponsored National Clinical Trials Network. His contributions to the field of neuro-oncology has been recognized with numerous awards, including the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan-Kettering Cancer Center, and the Gary Lichtenstein Humanitarian Award from Voices Against Brain Cancer. Dr. Lassman earned his BS and MS degrees in Molecular Biophysics and Biochemistry as part of a combined 4-year program at Yale University, and went on to received his MD from Columbia University College of Physicians and Surgeons. Dr. Lassman subsequently completed his residency at the Neurological Institute of NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, and fellowship in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, where he then joined the faculty and served as fellowship director.

Departmental Appointments

Department of Neurology
Division of Neuro-oncology

Board Certifications

Neurology

Areas of Expertise

Neuro-Oncology
Cancer Care
Brain & Spinal Tumors
Acoustic Neuroma
Astrocytoma
Anaplastic Astrocytoma
Brain Tumor
Brain Metastases
Brain Stem Glioma
Brain Cancer
Carcinomatous meningitis
Chordoma
Choroid Plexus Papilloma
Choroid Plexus Carcinoma
Ependymoma
Gliomas
Glioblastoma
Glioblastoma Multiforme
Hemangioblastoma
Leptomeningeal metastases
Medulloblastoma
Meningioma
Metastatic Cancer
Mixed Glioma
Neurofibromatosis
Oligodendroglioma
Oligoastrocytoma
Second Opinions
Spinal Cord Tumor
Spinal Tumors

Education and Training

MD, Columbia University College of Physicians and Surgeons
Internship: Mount Sinai Hospital
Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
Fellowship: Memorial Sloan-Kettering Cancer Center

Locations

Neurological Institute of New York
710 West 168th Street
New York, NY 10032
For new and current patient appointments, call:
(212) 342-0571
Fax:
(212) 342-1246

Centers / Institutes / Programs

Herbert Irving Comprehensive Cancer Center

Provider Affiliations

NewYork-Presbyterian/Columbia

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

Aetna [EPO, HMO, Medicare Managed Care, NY Signature, NYP Employee Plan, POS, PPO, Signature Administrators, Student Health]
Affinity [Essential Plan, Medicaid Managed Care]
AgeWell [Medicare Managed Care, Special Needs Plan]
Amida Care [Special Needs Plan]
Capital District Physician Health Plan [Capital District Physician Health Plan]
Cigna [EPO, Great West, HMO, POS, PPO]
Emblem/GHI [Medicare Managed Care, PPO]
Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
Empire Blue Cross Blue Shield [EPO, Medicare Managed Care, PPO]
Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
Healthfirst [Child/Family Health Plus, Leaf (Exchange), Medicaid Managed Care, Medicare Managed Care]
Local 1199 [Local 1199]
MagnaCare [MagnaCare]
Multiplan [Multiplan]
MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
Oxford Health Plans [Freedom, Liberty]
UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
VNSNY CHOICE [Medicare Managed Care, SelectHealth, Special Needs Plan]
WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider accepts new patients

Appointment Phone Number: (212) 342-0571

Contact Info

212-342-0571
212-342-1246

Presentations

Selected Invited Presentations

Grand Rounds, Columbia University, College of Physicians & Surgeons, Neurosurgery, July, 2001
Wireless Worries: Do Cell-phones Cause Brain Tumors?
Faculty, 4th Annual Future of Supportive Therapy in Oncology, Dallas, February, 2006
Central Nervous System Metastases
Faculty, Society for Neuro-Oncology Annual Meeting, November, 2007
The Issue of Tissue: Clinical Trial Design for Targeted Therapies in Glioma
Faculty, 2nd Annual Symposium on Gliomas & Secondary Brain Tumors, November, 2008
Update on Treatment of Recurrent Glioblastoma
Grand Rounds, Barrow Neurological Institute, Neurology, October, 2008
Glioblastoma
Faculty, Education Day, Society for Neuro-Oncology, Annual National Meeting, November, 2008
Chemotherapy for Newly Diagnosed Anaplastic Oligodendroglioma?
Faculty, Education Session, ASCO, Annual National Meeting, May, 2009
Management of Newly Diagnosed Anaplastic Oligodendroglioma
Faculty, 3nd Annual Symposium on Gliomas & Secondary Brain Tumors, November, 2009
Current Approaches to Anaplastic Oligodendroglioma
Grand Rounds, Columbia University College of Physicians & Surgeons, Neurology, Sept., 2009
Glioblastoma
Platform Presentation, Joint Meeting of the Society for Neuro-Oncology and the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors, 2009
International Retrospective Study of 1000+ Adults with Anaplastic Oligodendroglial Tumors
Grand Rounds, North Shore-LIJ Health System, Neurology, March, 2010
Glioblastoma
Grand Rounds, NYU-Post Graduate Medical School, Neurology, June, 2010
Newly Diagnosed Glioblastoma
Platform Presentation, Society for Neuro-Oncology, Annual Meeting, November, 2011
Recursive Partitioning Analysis of Prognostic Variables in Newly Diagnosed Anaplastic Oligodendroglial Tumors
Grand Rounds, Columbia University College of Physicians & Surgeons, Neurology, January 2012
Glioblastoma: Past, Present, and Future
Grand Rounds, Columbia University College of Physicians & Surgeons, Hematology Oncology, January 2012
Brain Metastases
Grand Rounds, Columbia University College of Physicians & Surgeons, Neurosurgery, March 2012
Oligodendrogliomas
Neuro-Oncology Symposium, John Theurer Cancer Center at Hackensack University Medical Center, April 2012
Glioblastoma
Faculty, Weill Cornell Brain and Spine Center, Weill Cornell Cancer Center, June 2012
Brain Tumor Biotech Summit
Discussant, Publications Scientific Session, Radiation Therapy Oncology Group, Semi-annual meeting, June 2012
Molecular Markers in High Grade Gliomas: Effects on Practice?
Invited Speaker, Society for Neuro-Oncology, Annual National Meeting, November, 2012
Anaplastic Glioma: New Challenges in the Era of Molecularly Based Treatment: PCV or Temozolomide?
Faculty, American College of Radiation Oncology Annual meeting, February 2013
Anaplastic Oligodendrogliomas: Latest treatments and controversies
Grand Rounds, Weill Cornell Medical College , Neurosurgery, March 2013
Glioblastoma: Past, Present, and Future
Invited Lecturer, Columbia University, Mailman School of Public Health, Neuroepidemiology, April 2013
Brain Tumor Epidemiology
Seminar Speaker, Columbia University College of Physicians & Surgeons, Hematology-Oncology, April 2013
Glioblastoma: Past, Present, and Future
Research Seminar Series, Columbia University College of Physicians & Surgeons, Pediatric Hematology/Oncology, April 2013
Anaplastic Oligodendrogliomas: Latest Treatments and Controversies
Grand Rounds, Columbia University College of Physicians & Surgeons, Radiation-Oncology, May 2013
Anaplastic Oligodendrogliomas: Latest Treatments and Controversies
Grand Rounds, Columbia University College of Physicians & Surgeons, Neurosurgery, May 2013
Anaplastic Oligodendrogliomas: Latest Treatments and Controversies
Faculty, Update in Neuro-Oncology, Omniprex International, March 2013
Low Grade Gliomas and Anaplastic Gliomas
Faculty, American Society for Clinical Oncology, Annual National Meeting, June 2013
Scientific Discussant, Clinical Science Symposium: The Importance of Molecular Markers in Anaplastic Gliomas
Faculty, Society for Neuro-Oncology, Annual National Meeting, November, 2013
Controversies in Neuro-Oncology: PCV vs. Temozolomide for Anaplastic Oligodendrogliomas
Faculty, Weill Cornell Brain and Spine Center, Weill Cornell Cancer Center, June 2013
Brain Tumor Biotech Summit

Teaching Responsibilities

Neurology resident didactic speaker on central nervous system tumors and metastases. Teaching attending for outpatient and inpatients in Neurology Department.

Committees / Societies / Memberships

American Medical Association, Member

American Academy of Neurology, Member

Society for Neuro-Oncology, Member

American Society of Clinical Oncology, Member

Radiation Therapy Oncology Group, Brain Committee

Society for Neuro-Oncology, Annual Meeting, Abstract Review Committee

NIH Common Terminology Criteria for Adverse Events (CTCAE) Revision Committee

United Council for Neurologic Subspecialties Board, Neuro-Oncology Representative

Voices Against Brain Cancer Medical Advisory Board

American Society of Clinical Oncology, Scientific Program Committee, CNS Track

American College of Radiation Oncology, Scientific Program Committee

Honors and Awards

Neurology Resident Teaching Award, Memorial Sloan-Kettering Cancer Center/Weill Medical College of Cornell University
Preuss Award in Neuro-Oncology, American Academy of Neurology
Boyer Clinical Research Award, Memorial Sloan-Kettering Cancer Center
Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer

NIH Grants

COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)
Aug 14 2019 - Jul 31 2025
A PHASE 1B/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF BGB-290 IN COMBINATION WITH RADIATION THERAPY AND/OR TEMOZOLOMIDE IN SUBJECTS WITH FIRST-LINE OR RECURRENT/REFRACTORY GLIOBLASTOMA (P&S Industry Clinical Trial)
Aug 30 2018 - Aug 30 2023
EGFR AND RELATE BIOMARKERS N GBM, CONCORDANCE ACROSS METHODS AND MAINTENANCE OVER DISEASE ARC. (P&S Industry Clinical Trial)
Jul 13 2018 - Jul 13 2023
PHASE 3B STUDY FOR MANAGEMENT OF OCULAR SIDE EFFECTS IN SUBJECTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN (ABT-414) (P&S Industry Clinical Trial)
Jul 9 2018 - Jul 9 2023
SERVICE AGREEMENT: A TWO-PART, PHASE I/IIA DOSE-ESCALATION CLINICAL TRAIL TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN (P&S Industry Clinical Trial)
Dec 6 2017 - Dec 6 2022
A TWO-PART, PHASE I/IIA DOSE-ESCALATION STUDY TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN RECURRENT GBM SUBJECTS. (P&S Industry Clinical Trial)
Nov 29 2017 - Nov 29 2022
GBM AGILE GLOBAL ADAPTIVE TRIAL MASTER PROTOCOL (Private)
Jun 11 2019 - Jun 10 2022
A STUDY OF RADIOLOGICALLY EVIDENT TREATMENT EFFECTS IN SUBJECTS WITH GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)
May 15 2017 - May 15 2022
A PHASE 2, MULTICENTER STUDY OF TESEVATINIB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 18 2017 - Apr 18 2022
A PHASE II, OPEN LABEL, MULTI-CENTER STUDY IN ADULTS WITH RECURRENT HIGH GRADE GLIOMA (Federal Gov)
Apr 9 2019 - Apr 8 2022
PHASE I/II DOSE ESCALATION TRIAL TO ASSESS SAFETY OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)
Feb 4 2015 - Feb 4 2020
PHASE II TRIAL OF VELCADE? (BORTEZOMIB) IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Dec 11 2014 - Dec 11 2019
A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE FAILED WHOLE BRAIN RADIATION THERAPY (P&S Industry Clinical Trial)
Jul 18 2014 - Jul 18 2019
IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)
Jul 15 2016 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
A PHASE II, TWO TIER STUDY EVALUATING THE EFFICACY AND SAFETY OF SELINEXOR (KPT 330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA AFTER FAILURE OF RADIATION THERAPY AND TEMOZOLOMIDE (P&S Industry Clinical Trial)
Jun 20 2014 - Jun 20 2019
A PHASE IB/II, OPEN LABEL, MULITCENTER STUDY OF INC280 IN COMBINATION WITH BUPARLISIB IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
May 14 2014 - May 14 2019
A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF BGJ398 IN PATIENTS WITH RECURRENT RESECTABLE OR UNRESECTABLE GLIOBLASTOMA (P&S Industry Clinical Trial)
Mar 4 2014 - Mar 4 2019
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH-PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA (P&S Industry Clinical Trial)
Oct 2 2013 - Oct 2 2018
A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ABT-414 IN COMBINATION WITH RADIATION PLUS TEMOZOLOMIDE OR TEMOZOLOMIDE ALONE (P&S Industry Clinical Trial)
Aug 13 2013 - Aug 13 2018
AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PLX3397 IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (P&S Industry Clinical Trial)
Jul 26 2013 - Jul 26 2018
PHASE II STUDY OF AMG 386 WITH AND WITHOUT BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 23 2013 - Apr 23 2018
PILOT STUDY OF EGFR INHIBITION USING HIGH DOSE ADMINISTRATION OF ERLOTINIB WEEKLY FOR RECURRENT MALIGNANT GLIOMAS WITH EGFR VARIANT III MUTATION - PILOT STUDY OF EGFR INHIBITION FOR GMB (P&S Industry Clinical Trial)
Jan 10 2013 - Jan 10 2018
CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION (INTELLANCE 1) (RTOG 3508) (Private)
Sep 1 2015 - Aug 31 2016
A PHASE 2 STUDY OF MEDI-575 IN ADULT SUBJECTS WITH RECURRENTGLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Jan 5 2011 - Jan 5 2016
PHASE II CLINICAL TRIAL OF PERIFOSINE + TEMSIROLIMUS FOR RECURRENT GLIOBLASTOMA WITH TISSUE AND IMAGING CORRELATES OF RESPONSE (Private)
Jan 1 2013 - Dec 31 2015
COLUMBIA UNIVERSITY MEDICAL CENTER MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM (MB-CCOP) (Federal Gov)
Aug 6 2012 - May 31 2015
RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)
Jan 1 2009 - Dec 31 2014
PULSATILE KINASE INHIBITOR THERAPY FOR MALIGNANT GILOMA: PROOF OF CONCEPT CLINICAL TRIAL (Private)
Jun 1 2013 - May 31 2014

Department of Neurology